

=> d his

```
(FILE 'USPAT' ENTERED AT 12:39:52 ON 17 DEC 1998)
L1      78974 S 514*?/CCLS
L2      219 S L1 AND FLUOXETINE
L3      81 S L2 AND ANHYDROUS?
L4      53 S L3 AND CELLULOSE# AND STARCH
L5      118 S L2 AND LACTOSE#
L6      101 S L2 NOT L5
L7      8 S L6 AND CELLULOSE# AND STARCH
L8      2 S L7 AND ANHYDROUS?
```

=> d 17 leg 2

US PAT NO: 5,780,051 [IMAGE AVAILABLE] L7: 2 of 8
DATE ISSUED: Jul. 14, 1998
TITLE: Methods and articles of manufacture for nicotine cessation
and monitoring nicotine use
INVENTOR: Amruta R. Eswara, Beverly, MA
Neal Muni, N. Reading, MA
F. Howard Schneider, Yarmouth, MA
Peter J. Mione, Abington, MA
ASSIGNEE: DynaGen, Inc., Cambridge, MA (U.S. corp.)
APPL-NO: 08/779,281
DATE FILED: Jan. 22, 1997
ART-UNIT: 165
PRIM-EXMR: Carlos Azpuru
LEGAL-REP: Wolf, Greenfield & Sacks, P.C.

US PAT NO: 5,780,051 [IMAGE AVAILABLE] L7: 2 of 8
US-CL-CURRENT: 424/449, 423, 425, 426, 451, 501, 502; 514/810,
811, 812, 813, 953, 955, 963,
965

SUMMARY:

BSUM(29)

Antidepressants . . . Dothiepin Hydrochloride; Doxepin Hydrochloride;
Duloxetine Hydrochloride; Eclanamine Maleate; Encyprate; Etoferidone
Hydrochloride; Fantridone Hydrochloride; Fenmetozole Hydrochloride;
Fenmetramide; Fezolamine Fumarate; Fluotracen Hydrochloride;
Fluoxetine; **Fluoxetine** Hydrochloride; Fluparoxan Hydrochloride;
Gamfexine; Guanoxifen Sulfate; Imafen Hydrochloride; Imiloxan
Hydrochloride; Imipramine Hydrochloride; Indeloxazine Hydrochloride;
Intripyline Hydrochloride; Iprindole; Isocarboxazid; Ketipramine
Fumarate;. . .

DETDESC:

DETD(14)

The . . . diethyl barbiturate area 33 to the top indicator 41.
Examples of paper which may be used in this invention include
cellulose, fiberglass and tuff glass. The preferred paper is
cellulose. The most preferred paper is 100% **cellulose** (Absorbent
Paper Grade #222; Ahlstrom Filtration Inc., Mount Holly Springs, Pa.).

DETDESC:

DETD(75)

TABLE 7

Lobeline Sulfate	2.5 mg
Mannitol, USP (DC grade)	31.5 mg
Microcryst, Cellulose	40.35 mg
Sodium Starch Glycolate NF	2.6 mg
Sodium Saccharin, USP	0.5 mg
Flavor S.D. Peppermint, FCC	0.75 mg
Magnasweet MM. . . .	

DETDESC:

DETD(76)

TABLE 8

COMPONENT	WEIGHT PER DOSE (mg)
Lobeline sulfate	7.50
Mannitol	30.30

Microcrystalline **cellulose** (FMC) 4.00

34.00

Sodium **starch** glycolate (EXPLS TAB

2.60

Mendell)

Magnesium stearate NF

0.50

Colloidal silicon dioxide (Aerosil 200)

0.40

Sodium saccharin. . .

DETDESC:

DETD(83)

Microcrystalline **cellulose**, mannitol and sodium **starch** glycolate provide the tablet core. The **cellulose** and **starch** facilitate binding the core ingredients and facilitate tablet disintegration in the presence of moisture. The relative amounts of these ingredients. . .

=> d 14 1-53

1. 5,846,982, Dec. 8, 1998, Inhibition of serotonin reuptake; James E. Audia, et al., **514/318, 324**; 546/193, 202 [IMAGE AVAILABLE]
2. 5,792,760, Aug. 11, 1998, Bisindoles as tachykinin receptor antagonists; Philip A. Hipskind, et al., **514/212, 323, 414**; 540/602; 546/201; 548/455 [IMAGE AVAILABLE]
3. 5,789,402, Aug. 4, 1998, Compounds having effects on serotonin-related systems; James E. Audia, et al., **514/213, 217, 278, 290, 299, 373, 415**; 540/586, 593, 596; 546/16, 101, 112, 148, 200, 201; 548/427, 454, 455, 465, 470, 503, 518 [IMAGE AVAILABLE]
4. 5,741,789, Apr. 21, 1998, Compounds having effects on serotonin-related systems; David J. Hirschman, et al., **514/210, 213, 278, 323**; 540/543, 586, 593, 597; 546/16, 17, 101, 140, 143, 177, 187, 195, 201 [IMAGE AVAILABLE]
5. 5,708,035, Jan. 13, 1998, Methods of use and compositions of R(-) **fluoxetine**; James W. Young, et al., **514/649, 651, 654** [IMAGE AVAILABLE]
6. 5,696,142, Dec. 9, 1997, Aminoalkyloximes; Gregory M. Shutske, et al., **514/399, 212, 227.8, 326, 397**; 540/603; 544/60; 546/210; 548/314.7, 336.1 [IMAGE AVAILABLE]
7. 5,686,483, Nov. 11, 1997, Aminoalkyloximes; Gregory M. Shutske, et al., **514/428, 183, 211, 212, 227.5, 227.8, 228.2, 233.8, 237.2, 238.2, 322, 331, 422**; 540/450, 467, 480, 481, 482, 483, 544, 596, 598, 602, 603, 604, 609, 610; 544/56, 59, 60, 62, 122, 130, 139, 141, 162, 187, 189; 546/199, 208, 210, 221, 229, 232; 548/312.4, 313.7, 314.7, 336.1, 341.5, 518, 539, 569; 564/256 [IMAGE AVAILABLE]
8. 5,686,447, Nov. 11, 1997, Aminoalkyloximes for treating depression and affective disorders; Gregory M. Shutske, et al., **514/212, 183, 211, 227.5, 227.8, 228.2, 233.8, 237.2, 238.2, 322, 331, 422, 428**; 540/450, 467, 480, 481, 482, 483, 544, 596, 598, 602, 603, 604, 609, 610; 544/56, 59, 60, 62, 122, 130, 139, 141, 162, 187, 189; 546/199, 208, 210, 221, 229, 232; 548/312.4, 313.7, 314.7, 336.1, 341.5, 518, 539, 569; 564/256 [IMAGE AVAILABLE]
9. 5,686,446, Nov. 11, 1997, Aminoalkyloximes; Gregory M. Shutske, et al., **514/212, 183, 211, 227.5, 227.8, 228.2, 233.8, 237.2, 238.2, 322, 331, 422, 428**; 540/450, 467, 480, 481, 482, 483, 544, 596, 598, 602, 603, 604, 609, 610; 544/56, 59, 60, 62, 122, 130, 139, 141, 162, 187, 189; 546/199, 208, 210, 221, 229, 232; 548/312.4, 313.7, 314.7, 336.1, 341.5, 518, 539, 569; 564/256 [IMAGE AVAILABLE]
10. 5,684,021, Nov. 4, 1997, Aminoalkyloximes for treating depression and affective disorders; Gregory M. Shutske, et al., **514/331, 183, 211, 212, 227.5, 227.8, 228.2, 233.8, 237.2, 238.2, 322, 422, 428**; 540/450, 467, 480, 481,

482, 483, 544, 596, 598, 602, 603, 604, 609, 610; 544/56, 59, 60, 62, 122, 130, 139, 141, 162, 187, 189; 546/199, 208, 210, 221, 229, 232; 548/312.4, 313.7, 314.7, 336.1, 341.5, 518, 539, 569; 564/256 [IMAGE AVAILABLE]

11. 5,665,756, Sep. 9, 1997, Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders; Gregory M. Shutske, et al., **514/399**, 183, 211, 212, **213**, **227.5**, **227.8**, **235.8**, **237.8**, **315**, **322**, **326**, **336**, **357**, **392**, **396**, **422**, **423**, **431**, **450**, **640**; 540/450, 467, 480, 481, 482, 483, 544, 596, 598, 603, 604, 609; 544/56, 60, 122, 130, 162, 187, 189; 546/210, 221, 229; 548/312.4, 313.7, 314.7, 336.1, 341.5, 539; 564/256 [IMAGE AVAILABLE]

12. 5,648,396, Jul. 15, 1997, Methods for treating depression and other disorders using optically pure R (-) **fluoxetine** and monoamine oxidase inhibitor; James W. Young, et al., **514/651**, **650**, **654**, **655** [IMAGE AVAILABLE]

13. 5,648,367, Jul. 15, 1997, Aminoalkyloximes; Gregory M. Shutske, et al., **514/330**, 212, **227.8**, **316**, **322**, **326**, **397**, **399**, **640**; 540/480, 544, 603; 544/58.5, 60, 96, 139; 546/187, 189, 199, 225; 548/314.7, 336.1, 523, 569; 564/256 [IMAGE AVAILABLE]

14. 5,631,270, May 20, 1997, Substituted pyridinylamino-1H-indoles, 1H-indazoles, 2H-indazoles, benzo [b]; Richard C. Effland, et al., **514/337**, **338**, **339** [IMAGE AVAILABLE]

15. 5,627,196, May 6, 1997, Compounds having effects on serotonin-related systems; James E. Audia, et al., **514/323**, **231.5**, **235.2**, **255**, **316**; 544/124, 360; 546/187, 195, 201 [IMAGE AVAILABLE]

16. 5,614,523, Mar. 25, 1997, Compounds having effects on serotonin-related systems; James E. Audia, et al., **514/252**, **253**, **254**, **414**; 544/238, 253, 358, 359 [IMAGE AVAILABLE]

17. 5,613,958, Mar. 25, 1997, Transdermal delivery systems for the modulated administration of drugs; Frank Kochinke, et al., 604/307; 424/449; **514/947**; 602/52, 54, 58; 604/890.1 [IMAGE AVAILABLE]

18. 5,607,691, Mar. 4, 1997, Compositions and methods for enhanced drug delivery; Ron L. Hale, et al., 424/449; **514/1**, **2**, **26**, **169**, **183**, **553**, **556**; 604/20 [IMAGE AVAILABLE]

19. 5,597,826, Jan. 28, 1997, Compositions containing sertraline and a 5-HT_{1D} receptor agonist or antagonist; Harry R. Howard, et al., **514/255**, **247**, **256**, **303**, **319**, **357**, **428**, **429**, **647**, **657**, **811** [IMAGE AVAILABLE]

20. 5,589,511, Dec. 31, 1996, Method for treating migraine headaches using optically pure S(+) **fluoxetine**; James W. Young, et al., **514/646**, **649**, **651** [IMAGE AVAILABLE]

21. 5,576,321, Nov. 19, 1996, Compounds having effects on serotonin-related systems; Joseph H. Krushinski, Jr., et al., **514/255**, **323**, **409**, **414**, **415**, **422**, **427**, **469**, **470**; 544/154, 373; 546/201; 548/408, 465 [IMAGE AVAILABLE]

22. 5,519,032, May 21, 1996, Substituted aminothienopyridines, pharmaceutical composition and use; Richard C. Effland, et al., **514/301**, **307**; 546/114 [IMAGE AVAILABLE]

23. 5,510,350, Apr. 23, 1996, Benzanilide derivatives; Alexander W. Oxford, et al., **514/252** [IMAGE AVAILABLE]

24. 5,457,121, Oct. 10, 1995, Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake; John M. Schaus, et al., **514/412**; 548/453 [IMAGE AVAILABLE]
25. 5,424,322, Jun. 13, 1995, A personality disorder treatment method and composition; Richard C. Effland, et al., **514/339** [IMAGE AVAILABLE]
26. 5,403,824, Apr. 4, 1995, Methods for the treatment of osteoporosis; Sharyn M. D'Souza, et al., **514/12, 14, 15, 16, 17, 18, 19** [IMAGE AVAILABLE]
27. 5,358,948, Oct. 25, 1994, Benzanilide derivatives; John Bradshaw, et al., **514/252**; 544/360 [IMAGE AVAILABLE]
28. 5,356,910, Oct. 18, 1994, Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder; Sathapana Kongsamut, et al., **514/339, 333, 412, 414, 415, 419** [IMAGE AVAILABLE]
29. 5,356,893, Oct. 18, 1994, Benzanilide derivatives; John Bradshaw, et al., **514/227.2, 227.8, 235.8, 252, 255**; 544/54, 59, 60, 106, 121, 176, 229, 359, 360, 364, 365, 372, 374, 393, 395; 548/131, 539, 953; 556/402; 558/49, 52, 54; 560/30, 41, 103; 562/442; 564/90, 183, 366; 568/6, 337, 607, 812; 570/182 [IMAGE AVAILABLE]
30. 5,340,810, Aug. 23, 1994, Benzanilide derivatives; John W. Clitherow, et al., **514/252**; 544/229, 366, 367, 385, 393, 395; 548/110, 127, 128, 131, 133, 136, 143, 269.4; 560/103; 564/149, 253, 442 [IMAGE AVAILABLE]
31. 5,334,599, Aug. 2, 1994, Heteroaryl-8-azabicyclo[3,2,1]octanes as antipsychotic agents, 5-HT₂ receptor antagonists and inhibitors of the reuptake of serotonin; Edward J. Glamkowski, et al., **514/304**; 546/126 [IMAGE AVAILABLE]
32. 5,328,920, Jul. 12, 1994, Substituted (pyridinylamino)-indoles; Richard C. Effland, et al., **514/339, 333, 338**; 546/256, 271.1, 272.1, 275.7, 277.4, 281.1, 284.1 [IMAGE AVAILABLE]
33. 5,328,918, Jul. 12, 1994, Substituted pyridinylamino 1H-indazoles; Richard C. Effland, et al., **514/338**; 546/271.1, 275.7, 277.4, 281.1 [IMAGE AVAILABLE]
34. 5,252,581, Oct. 12, 1993, Substituted aminothienopyridines, pharmaceutical composition and use; Richard C. Effland, et al., **514/301**; 546/114 [IMAGE AVAILABLE]
35. 5,250,572, Oct. 5, 1993, (R)-norfluoxetine in method for occupying serotonin IC receptors; David W. Robertson, et al., **514/651, 811, 813, 909, 910**; 564/304, 347 [IMAGE AVAILABLE]
36. 5,250,571, Oct. 5, 1993, (S)-norfluoxetine in method of inhibiting serotonin uptake; Ray W. Fuller, et al., **514/651, 811, 813, 909, 910**; 564/304, 347 [IMAGE AVAILABLE]
37. 5,248,677, Sep. 28, 1993, Biogenic amine uptake inhibitors; Fatima Z. Basha, et al., **514/217, 183, 215, 287**; 540/476, 576; 546/65, 101 [IMAGE AVAILABLE]
38. 5,246,947, Sep. 21, 1993, Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression; Richard C. Effland, et al., **514/338**; 546/271.1, 277.4, 281.1 [IMAGE AVAILABLE]

39. 5,234,931, Aug. 10, 1993, Heteroaryl-8-azabicyclo[3.2.1]octanes as antipsychotic agents, 5-HT₂ receptor antagonists and inhibitors of the reuptake of serotonin; Edward J. Glamkowski, et al., **514/304**; 546/126, 132 [IMAGE AVAILABLE]
40. 5,229,401, Jul. 20, 1993, Substituted pyridinylamino benzo[b]thiophene compounds; Richard C. Effland, et al., **514/337**; 546/271.1, 275.7, 277.4, 281.1 [IMAGE AVAILABLE]
41. 5,202,319, Apr. 13, 1993, Substituted 3-amino-2,3,4,5-tetrahydro-1-aryloxy-3-benzazepines; Richard C. Effland, et al., **514/213**; 540/594 [IMAGE AVAILABLE]
42. 5,185,350, Feb. 9, 1993, Substituted pyridinylamino-1H-indoles, 1H-indazoles, 2H-indazoles, benzo (b)thiophenes and 1,2-benzisothiazoles; Richard C. Effland, et al., **514/339, 337, 338**; 546/271.1, 275.7, 277.4, 280.7 [IMAGE AVAILABLE]
43. 5,180,733, Jan. 19, 1993, Biogenic amine uptake inhibitors; Fatima Z. Basha, et al., **514/410, 411**; 548/421, 427 [IMAGE AVAILABLE]
44. 5,177,088, Jan. 5, 1993, Substituted 3-(pyridinylamino)-indoles; Richard C. Effland, et al., **514/339, 212, 235.2, 255, 318**; 540/597; 544/124, 131, 360; 546/147, 193, 194, 275.7, 277.4, 281.1 [IMAGE AVAILABLE]
45. 5,135,947, Aug. 4, 1992, 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors; David W. Robertson, et al., **514/466, 554, 651**; 549/443; 562/585; 564/352 [IMAGE AVAILABLE]
46. 5,104,899, Apr. 14, 1992, Methods and compositions for treating depression using optically pure **fluoxetine**; James W. Young, et al., **514/646** [IMAGE AVAILABLE]
47. 5,026,707, Jun. 25, 1991, Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes; James A. Nixon, et al., **514/255, 218**; 540/575; 544/336, 392, 395, 403 [IMAGE AVAILABLE]
48. 5,024,998, Jun. 18, 1991, Pharmaceutical formulations for parenteral use; Nicholas S. Bodor, 424/1.85, 94.1; **514/58, 777, 937**; 536/103 [IMAGE AVAILABLE]
49. 5,023,269, Jun. 11, 1991, 3-aryloxy-3-substituted propanamines; David W. Robertson, et al., **514/438, 357, 365, 471**; 546/334; 548/205; 549/75, 491 [IMAGE AVAILABLE]
50. 5,017,566, May 21, 1991, Redox systems for brain-targeted drug delivery; Nicholas S. Bodor, **514/58, 964, 965**; 536/103 [IMAGE AVAILABLE]
51. 4,996,235, Feb. 26, 1991, 3,4-diphenylbutanamines; David W. Robertson, et al., **514/649, 648, 656, 811**; 564/315, 316, 373, 374, 378, 387 [IMAGE AVAILABLE]
52. 4,956,388, Sep. 11, 1990, 3-aryloxy-3-substituted propanamines; David W. Robertson, et al., **514/651, 811, 813, 910**; 564/347, 352 [IMAGE AVAILABLE]
53. 4,876,282, Oct. 24, 1989, 1-Phenylalkylamines as selective serotonin uptake inhibitors; David W. Robertson, et al., **514/554, 555, 649, 811, 813**; 562/597; 564/304, 373 [IMAGE AVAILABLE]